{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-138257","form_type":"8-K","ticker":"AVIR","cik":"0001593899","company_name":"Atea Pharmaceuticals, Inc.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.577684+00:00","generated_at":"2026-06-15T13:21:48.687306+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Atea Q1 net loss $35.5M ($0.43/share); cash $620.5M; progresses bemnifosbuvir trials","bullets":["Net loss of $35.5M ($0.43 diluted EPS) vs $42.1M ($0.51) in Q1 2022; no revenue.","Cash, cash equivalents & marketable securities $620.5M at March 31, 2023 vs $646.7M at Dec 31, 2022.","R&D expense $29.0M, G&A $12.6M; both roughly flat YoY; interest income rose to $6.3M.","FDA granted Fast Track designation for bemnifosbuvir in COVID-19; Phase 3 SUNRISE-3 enrolling.","Phase 2 HCV combination (bemnifosbuvir + ruzasvir) dosing expected 2Q23; initial data 4Q23; dengue program deprioritized."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-138257","json":"https://secwatch.observer/filing/0001193125-23-138257.json","markdown":"https://secwatch.observer/filing/0001193125-23-138257.md","text":"https://secwatch.observer/filing/0001193125-23-138257.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1593899/000119312523138257/0001193125-23-138257-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1593899/000119312523138257/d391656d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T13:21:48.687306+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"adccd6735aa10ea9aca0374d0abb4bba1f905416","claim":"Atea Pharmaceuticals, Inc. reported financial results for the three months ended March 31, 2023.","evidence_excerpt":"On May 8, 2023, Atea Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the three months ended March 31, 2023 and other matters described in the press release.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593899/000119312523138257/0001193125-23-138257-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}